Scalper1 News
Biotech Sarepta Therapeutics (SRPT) got an upgrade and a price target increase Wednesday, a day after it said the FDA had finally accepted its filing for muscular-dystrophy drug eteplirsen. Late Tuesday, Sarepta said the agency had granted eteplirsen priority review and set its deadline for making an approval decision at Feb. 26. The drug treats cases of Duchenne muscular dystrophy (DMD) associated with a genetic mutation of exon 51, which Scalper1 News
Scalper1 News